THE widespread adoption of PCa screening in the United States by serum PSA testing has led to more men being diagnosed with a localized curable form 1 and yet controversy exists regarding over diagnosis and overtreatment of indolent tumors. 2 These concerns have influenced professional societies to recommend a shared decision making process between a man and his caregiver regarding PCa screening. 3, 4 However, there are no guidelines on shared decision making for PCa screening and only about 36% of men who undergo PCa screening do so following a joint decision with a caregiver. 5 DAs have been designed to provide accurate, easy to understand information for patients to help navigate The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
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* Equal study contribution. the decision making process. 6 To our knowledge the effect of specific DAs on screening preferences and comfort with the screening decision making process remains unknown.
We evaluate the effect of 6 published DAs from major professional societies on PCa screening preferences. We administered an online survey to men and women, and compared the preDA and post-DA likelihood of undergoing or recommending PCa screening. We also assessed the effect of DAs on comfort with the PCa screening decision making process and the quality of each DA.
MATERIALS AND METHODS

Decision Aids and Survey
Six major societies have DAs designed to educate and inform subjects about the risks, benefits and process of PCa screening (supplementary table 1, http://jurology. com/). Each DA was readily available and free online, reflecting what real patients or family members may access in clinical scenarios. The DAs were from the ASCOÒ, the ACS, the CDC, the USPSTF, the AAFP and the AUA.
We developed pre-DA and post-DA surveys (supplementary Appendix 1, http://jurology.com/). Pretest questions included demographic information and comorbid conditions. To assess the intent to undergo or recommend PCa screening before and after reading the DA we used a 100-point Likert scale with 100 indicating most likely. Posttest questions also assessed the effect of the DA on participant comfort with the PCa screening decision making process and participant opinions on DA content and quality.
After assessing the impact of reading the single DA that each participant received we gave each participant the summary statements of all 6 professional societies (supplementary Appendix 2, http://jurology.com/). We then asked the participants to again report an opinion of PCa screening.
Study Participants and Design
We obtained ethics approval for exemption status from the Northwestern University institutional review board. Using ResearchMatch (https://www.researchmatch.org/), an online national research study recruitment registry, we distributed the survey and decisions aids anonymously to volunteers 18 years old or older throughout the United States. 7 We randomized participants to receive 1 of the 6 DAs based on information available from a baseline survey according to age group (younger than 50, 50 to 59, 60 to 69 or older than 69 years), race (Caucasian, African American, Asian or Pacific Islander, or other) and gender (male or female). We performed randomization using REDcap (https://www.project-redcap.org/), an online survey data storage and management application. 8 The survey was open from October 18, 2017 to November 19, 2017.
A survey invitation was sent to 47,633 e-mail addresses of volunteers who met study criteria. A total of 1,981 volunteers expressed interest in participating, of whom 1,838 (93%) completed the baseline survey and were randomized. Finally, 1,336 participants (67%) completed the entire survey and were analyzed in the final cohort.
Each pretest and posttest survey was identical except for the pretest URL link, which opened a new webpage to the DA to which each participant was randomly assigned. We asked each participant to take as much time as necessary to understand the information provided by the DA, after which they should continue to the posttest questions.
Outcomes
The primary study outcome was the change in the likelihood of undergoing or recommending PCa screening after exposure to a DA. This was assessed by asking participants, "If a doctor asked you right now to make a choice about whether or not you or a loved one should get screened for PCa, what is the likelihood you will undergo PCa screening or encourage a family member to undergo PCa screening (if you are not male or in the screening age group)?" The participants then selected the likelihood on a 100-point scale with 100 considered extremely likely.
The secondary outcome was a rephrasing of this question to assess the effect of the opinion of a caregiver. This was assessed similarly to the primary outcome with the phrasing, "If a doctor recommended you or a loved one to get screened for PCa, what is the likelihood that you will undergo PCa screening or encourage a family member to undergo PCa screening (if you are not male or in the screening age group)?" Other secondary outcomes included changes in comfort and knowledge about PCa screening, participant rating of the quality of each DA and correlation of demographic information with the intent to undergo or recommend PCa screening.
Composite comfort with the screening process and the quality of the DAs were based on the average of 6, 5-point Likert-scale questions, including questions 1 to 4, 6 and 7 in section 2 and questions 5 to 10 in section 4 (supplementary appendix 1, http://jurology.com/). Knowledge was assessed on 11 true/false questions about PCa and screening, including questions 1 to 9, 11 and 12 in the section (supplementary Appendix 1, http://jurology. com/).
Covariates
Participant baseline characteristics assessed included age, race and ethnicity (nonHispanic Caucasian, nonHispanic African American, Hispanic or other), gender, highest education attainment, annual income, type of health insurance, marital status, self-rating of overall health on a 100-point scale, smoking status, previous discussion with a caregiver regarding PCa screening, a personal history or close relative history of cancer and the number of comorbidities, including diabetes, chronic obstructive pulmonary disease, heart disease, high blood pressure and body mass index 35 kg/m 2 or greater.
Statistical Analysis
We used the Covariates associated with a higher likelihood of PCa screening included being divorced or separated compared to single or never married (likelihood score 6.37, 95% CI 1.85e10.89, p ¼ 0.006), having a close relative who died of cancer compared to not having a close relative with cancer (8.91, 95% CI 0.01e2.91, p <0.001) and having a previous discussion with a caregiver regarding PCa screening compared to no discussion (5.78, 95% CI 1.34e10.22, p ¼ 0.011, see table). These results were similar to those when a physician recommended screening, except the effect of a previous PCa screening discussion was no longer significant (p ¼ 0.157).
After exposure to any DA the average intent to undergo or recommend PCa screening decreased from 83.3 to 77.5 (change e5.8, p <0.001, fig. 1, a) . Reading the CDC or the AAFP DA did not alter the likelihood of screening (each p >0.2). Reading the USPSTF DA was associated with the largest decrease (change e16.0, 95% CI e19.3ee12.7, p <0.001).
When participants were asked about the likelihood of undergoing PCa screening or recommending screening based on a physician recommendation, the likelihood score decreased from 86.7 to 82.3 (change e3.2, p <0.001, fig. 1, b) . Similarly reading the CDC or the AAFP DA did not significantly alter the likelihood of screening (each p >0.1). Compared to exposure to the ASCO DA, exposure to the USPSTF DA was associated with a greater decrease in the change from the baseline likelihood (change e12.11, 95% CI e15.63ee8.60, p <0.001, fig. 2 ). The CDC DA and the AAFP DA were associated with increases in the baseline likelihood (3.67, 95% CI 0.16e7.18, p ¼ 0.041 and 4.18, 95% CI 0.68e7.69, p ¼ 0.019, respectively). When adjusting for all baseline characteristics, compared to exposure to the ASCO DA the results were similar when a physician recommended screening. However, exposure to the CDC DA or the AAFP DA was not associated with a significant difference (each p >0.1).
Comfort and Knowledge. The mean baseline composite score of comfort with PCa screening was After exposure to any DA the mean comfort score increased from 3.5 to 4.1 of 5 (p <0.001, fig. 3 ). No specific DA was superior for increasing comfort with screening compared to others ( fig. 2 ). The mean pretest score on knowledge questions was 9.6 of 11, which increased to 10.0 of 11 following DA exposure (p <0.001). Each individual DA was associated with a similar increase in correct knowledge based questions.
Decision Aid Quality
The mean composite quality score of DAs was 4.3 of 5 and DA quality measures varied minimally (supplementary table 4 We also assessed the direction of participant perception of DA bias. Relative to the ASCO DA, the USPSTF DA was associated with greater bias toward not screening (bias score e0.42, 95% CI e0.57ee0.26, p <0.001) while the DA from the AAFP was associated with greater bias toward screening (0.18, 95% CI 0.03e0.34, p ¼ 0.019, fig. 2 ).
Societal Recommendations
Participants were then exposed to society recommendation statements (supplementary Appendix 2, http://jurology.com/). Following this the average screening preferences decreased from 77.5 to 73.7 (change e3.8, p <0.001). Screening preferences did not change significantly in participants randomized to the ASCO and ACS DAs (each p >0.1). Preferences decreased further in participants randomized to the CDC DA (change e2.3, p ¼ 0.033), the USPSTF DA (change e2.6, p ¼ 0.024), the AAFP DA (change e10.1, p <0.001) and the AUA DA (change e5.7, p <0.001).
DISCUSSION
Several studies related to PCa screening suggest that DAs can improve knowledge and reduce decisional regret. 6, 9 Our online survey assessed participant preferences of PCa screening before and after exposure to randomly assigned DAs from 6 major professional societies. Our results suggest that exposure to most DAs made participants more comfortable with the PCa screening decision making process and decreased the likelihood of undergoing or recommending PCa screening. One explanation for this finding may be that most people assume that the benefits of any cancer screening outweigh the potential risks and DAs may help educate them on the risks and the benefits of screening.
Participants with a higher annual income and more education were less likely to elect PCa screening, suggesting that patients in these cohorts already may have been more informed of the potential risks associated with screening. Accordingly free and easily accessible DAs such as those assessed in the current study may be used more to reduce socioeconomic disparities in the knowledge of and the comfort with PCa screening. A recent assessment of the effect of the ACS DA in medically underserved men showed that it improved PCa knowledge.
9 Importantly the quality scores of each DA varied minimally, suggesting that all DAs were favorably received.
The USPSTF DA was associated with the greatest perception of bias against screening by study participants while the AAFP DA was perceived to be as biased but more in favor of screening (supplementary table 1, http://jurology.com/). Notably the USPSTF DA includes detailed definitions on the potential harms of screening such as over diagnosis, overtreatment, urinary incontinence and erectile dysfunction. This DA also includes a cartoon that explains how some PCa tumors are indolent. In contrast, the AAFP DA does not mention over diagnosis or overtreatment. It defines urinary incontinence and erectile dysfunction but minimally, which may minimize the effect of defining those adverse treatment effects. Finally, the AAFP DA describes watchful waiting in little detail and does not acknowledge that some men may never need treatment.
These subtle details may explain why the USPSTF DA was associated with the largest decrease in the screening likelihood score while the AAFP DA was not associated with any change. Ironically the AAFP currently recommends against routine screening (supplementary Appendix 2, http://jurology.com/). However, participants who read that DA were not less likely to elect screening after reading it.
Our study has limitations. The final participation rate was moderate at 67%, which may reflect a need for participant computer and internet skills. Participants largely had at least a college education, private or Medicare insurance and an income greater than $66,000. These data suggest that the overall study results are more generalizable to a population with higher socioeconomic status.
Notably the changes in screening preferences in this study were significant and yet relatively small. The survey responses were not provided in the setting of a health care encounter, which would be necessary to determine the real effect on patient decision making.
Finally, it is important to note that the USPSTF DA used in this study was published prior to the official release of the most recent recommendation statement. 4 However, the DA reflected the most recent grade C recommendation for screening among men 55 to 69 years old (supplementary Appendix 2, http://jurology.com/). Strengths of our study include the large number of participants, which allowed for the concurrent comparison of several DAs from high profile professional societies. Additionally, the randomized nature of the study minimized measured and unmeasured biases among the participants assigned to individual DAs. 
CONCLUSIONS
EDITORIAL COMMENTS
Despite the mortality benefit of PSA screening 1 and the improved specificity of detecting clinically significant disease with advanced imaging 2 prostate cancer screening remains controversial because of the over diagnosis of indolent disease and the treatment related impact on sexual and urinary function. The ultimate goal of any cancer screening DA is to promote preference congruent and well informed screening decisions. 3 Weiner et al measured the impact of various DAs on prostate cancer screening preferences in nearly 1,330 participants using a randomized survey. They found that on average the 6 DAs decreased the likelihood of undergoing or recommending PSA screening.
The AAFP was the only society to recommend against PSA screening in all age groups but surprisingly that DA had the least impact on altering PSA screening intentions. This suggests that not all DAs yield the intended results. Furthermore, it is unclear whether a 5-point decrease in the author likelihood scale reflects a clinically meaningful change in PSA screening preferences.
Importantly the DAs universally improved participant comfort with screening decisions, which most likely translates into a clinically important outcome. Overall it appears DAs can provide meaningful benefit to patients as they wrestle with assessing the risks and benefits of prostate cancer screening.
Decision aids should ideally promote clinical equipoise. However, the data from this study suggest some variation to which this is applied, given the differing results on how they altered the pre-exposure intent to undergo or recommend PSA screening. Although there was some change of opinion, a common theme is that the pre-exposure intent was unchanged in the majority of individuals who worked through any of these decision aids. The results are somewhat similar to our experience with testing a decision aid in a randomized controlled trial of a controversial aspect of prostate cancer care. 1 The trial revealed that while the impact on change was statistically and clinically relevant, it was still modest in the context of overall numbers.
Perhaps the real beneficiaries of a decision aid might be those who are undecided at the outset and unsure on how to move forward rather than those in whom there is a strong preexisting bias. Testing this specific population may help us better understand decision aid equipoise for competing options.
While there appears to be some benefit, these data provide some understanding of the current role of decision aids for prostate cancer screening, which at this stage appears to be limited.
